Regulatory press release

Dicot Pharma presents Year-End Report 2025 and invites to a webcast presentation

Uppsala, Sweden, February 18, 2026. Dicot Pharma AB publishes its Year-End Report for 2025. The report is available as an attached document and on www.dicotpharma.com. The company will present the report in a webcast on Wednesday February 18 at 12.00 CET, a broadcast that may also be viewed afterwards.

Fourth quarter, October-December 2025

Net sales amounted to SEK 0.0 (0.0) million
Earnings after financial items amounted to SEK -16.8 (-20.8) million
Earnings per share amounted to SEK -0.01 (-0.01)

Full year 2025

Net sales amounted to SEK 0.0 (0.0) million
Earnings after financial items amounted to SEK -80.2 (-57.7) million
Earnings per share amounted to SEK -0.04 (-0.05)

”The positive results from the phase 2a study of LIB-01 reported in October demonstrated a unique long-acting effect on erectile function lasting up to eight weeks after treatment. This represents a significant advancement over current treatments, moving beyond temporary symptom relief to potentially restore sexual vitality, self-confidence, intimacy, and quality of life”, comments Elin Trampe, CEO.

Significant events during the quarter

Positive topline results from the phase 2a study show improvement in erectile function at weeks 4 and 8, after only 3 days of oral treatment with LIB-01 at the start of the study. LIB-01 was well tolerated at all dose levels. The results mean that Dicot Pharma will proceed with the development according to plan with initiation of a phase 2b clinical.
A new patent application was filed based on the long-term effect of eight weeks documented in the phase 2a clinical trial, which distinguishes LIB-01 significantly from current treatments for erectile dysfunction.
New findings on the mechanism of action showed that LIB-01 affects the melanocortin system, well known for regulating functions such as sexual function and energy metabolism. The findings support LIB-01's potential to improve erectile function even in non-responders of current treatments and the possibility of use in other indication areas.
Agreement was signed with international CRO for preparatory activities for phase 2b, to be initiated during second half of 2026 and conducted in the US and Europe.

Significant events after the quarter

Dicot Pharma has been invited to present the company and its lead candidate drug, LIB-01, at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in February.

The interim report will be presented by CEO Elin Trampe and CFO Björn Petersson in a live broadcast from Direkt Studio today Wednesday February 18 at 12.00 CEST. The broadcast can be viewed on PRESENTATION or via a link at www.dicotpharma.com. The broadcast can be viewed afterwards via the same link.

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 17,000 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.